Prenosis utilizes its Immunix™ precision medicine platform to analyze biomarkers and clinical data, enabling real-time diagnostics and personalized treatment for patients at risk of sepsis. The Sepsis ImmunoScore™, the first FDA-authorized AI diagnostic for sepsis, integrates directly into hospital electronic medical records to enhance decision-making and improve patient outcomes.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis, a life-threatening response to infection, poses a significant challenge in acute care settings, leading to high mortality rates and hospital readmissions. Current diagnostic methods often rely on symptom-based assessments and traditional biomarkers, which may lack the precision needed for early and accurate detection of sepsis and prediction of adverse outcomes. This can result in delayed interventions and suboptimal treatment strategies.
Solution
Prenosis offers the Immunix precision medicine platform, which leverages machine learning algorithms and a comprehensive biomarker-clinical dataset to provide real-time diagnostics and personalized treatment strategies for patients at risk of sepsis. The Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, integrates seamlessly into hospital electronic medical records (EMRs) to enhance clinical decision-making. By analyzing a combination of routinely collected EMR data and protein biomarkers, the Sepsis ImmunoScore offers an early warning system that predicts the likelihood of a patient developing sepsis and experiencing adverse outcomes, enabling timely interventions and improved patient outcomes. The Immunix platform facilitates the development and validation of precision medicine tools, providing clinicians with a deeper understanding of each patient’s unique biological response to infection.
Target Audience
The primary target audience includes hospitals, healthcare providers, and clinical researchers seeking advanced diagnostic tools for early sepsis detection, improved patient outcomes, and enhanced compliance with sepsis management protocols.
Features
- AI-powered diagnostic tool that integrates biomarker and clinical data for real-time sepsis risk assessment
- First FDA-authorized AI diagnostic for sepsis
- Seamless integration into hospital EMR systems for streamlined workflow
- Advanced warning system that predicts the likelihood of a patient developing sepsis before meeting SEP-1 criteria
- Comprehensive analysis of 22 parameters to categorize an individual’s biological response and evaluate sepsis risk
- Access to the world’s largest biomarker-clinical dataset for infection in acute care
- Transparent model providing insights into how the Sepsis ImmunoScore is calculated for each patient
- Designed to improve SEP-1 bundle compliance and reduce hospital costs associated with sepsis